Cargando…
Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications
Cervical cancer is a public health problem of extensive clinical importance. Excision repair cross-complementation group 1 (ERCC1) was found to be a promising biomarker of cervical cancer over the years. At present, there is no relevant review article that summarizes such evidence. In this review, n...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875293/ https://www.ncbi.nlm.nih.gov/pubmed/36713431 http://dx.doi.org/10.3389/fimmu.2022.1065379 |
_version_ | 1784877934302986240 |
---|---|
author | Du, Pei Li, Guangqing Wu, Lu Huang, Minger |
author_facet | Du, Pei Li, Guangqing Wu, Lu Huang, Minger |
author_sort | Du, Pei |
collection | PubMed |
description | Cervical cancer is a public health problem of extensive clinical importance. Excision repair cross-complementation group 1 (ERCC1) was found to be a promising biomarker of cervical cancer over the years. At present, there is no relevant review article that summarizes such evidence. In this review, nineteen eligible studies were included for evaluation and data extraction. Based on the data from clinical and experimental studies, ERCC1 plays a key role in the progression of carcinoma of the uterine cervix and the therapeutic response of chemoradiotherapy. The majority of the included studies (13/19, 68%) suggested that ERCC1 played a pro-oncogenic role in both early-stage and advanced cervical cancer. High expression of ERCC1 was found to be associated with the poor survival rates of the patients. ERCC1 polymorphism analyses demonstrated that ERCC1 might be a useful tool for predicting the risk of cervical cancer and the treatment-related toxicities. Experimental studies indicated that the biological effects exerted by ERCC1 in cervical cancer might be mediated by its associated genes and affected signaling pathways (i.e., XPF, TUBB3, and. To move towards clinical applications by targeting ERCC1 in cervical cancer, more clinical, in-vitro, and in-vivo investigations are still warranted in the future. |
format | Online Article Text |
id | pubmed-9875293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98752932023-01-26 Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications Du, Pei Li, Guangqing Wu, Lu Huang, Minger Front Immunol Immunology Cervical cancer is a public health problem of extensive clinical importance. Excision repair cross-complementation group 1 (ERCC1) was found to be a promising biomarker of cervical cancer over the years. At present, there is no relevant review article that summarizes such evidence. In this review, nineteen eligible studies were included for evaluation and data extraction. Based on the data from clinical and experimental studies, ERCC1 plays a key role in the progression of carcinoma of the uterine cervix and the therapeutic response of chemoradiotherapy. The majority of the included studies (13/19, 68%) suggested that ERCC1 played a pro-oncogenic role in both early-stage and advanced cervical cancer. High expression of ERCC1 was found to be associated with the poor survival rates of the patients. ERCC1 polymorphism analyses demonstrated that ERCC1 might be a useful tool for predicting the risk of cervical cancer and the treatment-related toxicities. Experimental studies indicated that the biological effects exerted by ERCC1 in cervical cancer might be mediated by its associated genes and affected signaling pathways (i.e., XPF, TUBB3, and. To move towards clinical applications by targeting ERCC1 in cervical cancer, more clinical, in-vitro, and in-vivo investigations are still warranted in the future. Frontiers Media S.A. 2023-01-11 /pmc/articles/PMC9875293/ /pubmed/36713431 http://dx.doi.org/10.3389/fimmu.2022.1065379 Text en Copyright © 2023 Du, Li, Wu and Huang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Du, Pei Li, Guangqing Wu, Lu Huang, Minger Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications |
title | Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications |
title_full | Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications |
title_fullStr | Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications |
title_full_unstemmed | Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications |
title_short | Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications |
title_sort | perspectives of ercc1 in early-stage and advanced cervical cancer: from experiments to clinical applications |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875293/ https://www.ncbi.nlm.nih.gov/pubmed/36713431 http://dx.doi.org/10.3389/fimmu.2022.1065379 |
work_keys_str_mv | AT dupei perspectivesofercc1inearlystageandadvancedcervicalcancerfromexperimentstoclinicalapplications AT liguangqing perspectivesofercc1inearlystageandadvancedcervicalcancerfromexperimentstoclinicalapplications AT wulu perspectivesofercc1inearlystageandadvancedcervicalcancerfromexperimentstoclinicalapplications AT huangminger perspectivesofercc1inearlystageandadvancedcervicalcancerfromexperimentstoclinicalapplications |